Abstract:Background: The fight against cancer has started since its discovery and has not subsided to nowadays. Currently, the hybrid molecules have become a promising alternative to the standard chemotherapeutics for the treatment of multi-causal diseases, including cancers. Objective: Herein, we report the synthesis, biological evaluation, mathematical docking calculations and hydrolytic stability of the new bioconjugates of monofluorinated analogues of BIM-23052, containing second pharmacophore naphthalimide, caffeic acid or the tripeptide Arg-Gly-Asp. Methods: All new molecules are obtained using standard peptide synthesis on solid support. Anticancer potential is studied against a panel of tumor cell lines included human mammary carcinoma cell lines MCF-7 (ER+, PR+ and Her-2-); MDA-MB-231 (ER-, PR- and Her-2-), as well as cell lines BALB 3T3 (mouse embryonic fibroblasts) and MCF-10A (human breast epithelial cell line). Results: The IC50 values found in the MCF-10A cell line assay were used to calculate the selective index (SI). The highest SI relative to MCF-7, with a value of 2.62 is shown by the compound Npht- Gly-D-Phe-Phe(4-F)-Phe-D-Trp-Lys-Thr-Phe-Thr-NH2. In MCF-10 cells, the weakest antiproliferative effect was caused by the same compound (IC50 = 622.9 ± 23.91 μM), which makes this analogue a good candidate for the new anticancer medical drug. Unfortunately, the hydrolytic stability studies reveal that this bioconjugate is the most unstable of hydrolysis under physiological conditions in the body. Conclusion: Even with lower anticancer activity and selectivity in comparison with Npht-Gly-DPhe- Phe(4-F)-Phe-D-Trp-Lys-Thr-Phe-Thr-NH2, the compound Arg-Gly-Asp-D-Phe-Phe(4-F)-Phe- D-Trp-Lys-Thr-Phe-Thr-NH2 is the best candidate between three investigated bioconjugates for practical application due to combination of activity and stability profiles. Mathematical docking calculation also reveals that synthesized bioconjugates show selectivity according to different somatostatin receptors on the surface of different cell lines.

Synthesis of Novel Protected Nα(ω-Drug) Amino Acid Building Units for Facile Preparation of Anticancer Drug-Conjugates

Amino Acid Conjugates of Aminothiazole and Aminopyridine As Potential Anticancer Agents: Synthesis, Molecular Docking and in Vitro Evaluation.

Novel Peptide–Drug Conjugates with Dual Anticancer Activity

Polypeptides–Drug Conjugates for Anticancer Therapy

Polymeric Prodrug by Supramolecular Polymerization

Assemblies of Peptide-Cytotoxin Conjugates for Tumor-Homing Chemotherapy

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

Synthesis of Protein Nano-Conjugates for Cancer Therapy

Peptide-Drug Conjugate: A Novel Drug Design Approach

Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy

Peptide-Drug Conjugates: A New Hope for Cancer Management

Synthesis of Amino‐cosubstituted Polyorganophosphazenes and Fabrication of Their Nanoparticles for Anticancer Drug Delivery

Novel N -Methylated Cyclodepsipeptide Prodrugs for Targeted Cancer Therapy

One-pot two-step catalytic synthesis of 6-amino-2-pyridone-3,5-dicarbonitriles enabling anti-cancer bioactivity

Synthesis, Anticancer Activity, Docking Calculations and Hydrolytic Stability Studies of Bioconjugates of Monofluorenated Analogue of BIM- 23052

Synthesis, Characterization, In Vitro Anticancer Potentiality, and Antimicrobial Activities of Novel Peptide–Glycyrrhetinic-Acid-Based Derivatives

Synthesis of site‐specific Fab‐drug conjugates using ADP‐ribosyl cyclases

Highly Cytotoxic Cryptophycin Derivatives with Modification in Unit D for Conjugation

Design, Synthesis and Antitumor Activity of Dimeric Bile Acid-Amino Acid Conjugates

Peptide-drug co-assembling: A potent armament against cancer

Drug-induced hierarchical self-assembly of poly(amino acid) for efficient intracellular drug delivery